Packaged food stocks have significantly underperformed pharmaceutical stocks over the past year, driven largely by concerns over GLP-1 weight-loss drugs impacting food demand. While Eli Lilly's stock soared 74%, many food companies like Campbell's and General Mills saw declines. However, some food stocks like Kraft Heinz and Hershey have shown gains this year, and ETFs tracking food and pharmaceuticals reveal a more nuanced picture than the broad "food so hated" label suggests. Investors should be cautious as the GLP-1 impact remains uncertain, and some food stocks are recovering, indicating the sentiment gap may be closing rather than presenting a clear buying opportunity.
More than 200 companies are actively developing over 240 Alzheimer's disease therapies, with around 20 drugs in late-stage trials and many others in earlier phases. Key players include Eli Lilly, Biogen, Johnson & Johnson, and Eisai, focusing on inno...
Goldman Sachs has increased its price target for Eli Lilly stock to $1,413, signaling an 8.87% potential upside amid strong revenue growth in the competitive weight-loss drug market. Despite projected revenue rising 25.59% to $22.11 billion, earnings...
Eli Lilly's stock rose 4% following a positive recommendation from the European Medicines Agency for its oral obesity pill, Foundayo, which is now close to final approval in the EU. This pill offers dosing flexibility and treats both weight managemen...
Eli Lilly reported a strong 47.7% revenue growth last quarter, driven by its expanding weight-loss drug franchise including Mounjaro and Zepbound. Analysts project that a $1,000 investment in the company could grow to about $1,830 by 2031, reflecting...
Eli Lilly reported strong Q2 earnings with revenue up 47.67% and EPS beating estimates, driven by high sales of its obesity drug Mounjaro. The company raised its 2026 revenue guidance to $85-$87 billion and is optimistic about the upcoming U.S. filin...
